XNGF – Xtreme Natural Growth Factor

Home Forums Kosttillskott XNGF – Xtreme Natural Growth Factor

  • This topic is empty.
Viewing 5 posts - 1 through 5 (of 5 total)
  • Author
    Posts
  • #84803
    #852346

    Någon som har lust att uttala sig om dessa kapslar, XNGF – Xtreme Natural Growth Factor. Är det bara skit eller kan det funka och isåfall fins det några biefekter?

    #852347

    Lista innehållet..

    #852348

    om det är XYIENCE XNGF Xtreme Natural Growth Factor han menar så finns där:

    Nutrition Facts
    Serving Size 3 x-caps
    Servings Per Container 30
    Amount Per Serving
    % Daily Value

    Alpha GPC (Alpha-Glycerylphospharylcholine) 440 mg

    Bacopa Monniera Extract 50 mg

    Macuna pruriens (Dopa Bean) Standardized 15% L-Dopa (L-Dihydroxphenylaianine) 660 mg

    *percent Daily Values are based on a 2,000 calorie diet.

    #852349

    Det finns inte tillräckligt med info för att veta exakt hur en tränande skulle få nytta från det men det finns lite intressanta studier..

    Quote:
    Mucuna pruriens in Parkinson’s disease: a double blind clinical and pharmacological study.
    J Neurol Neurosurg Psychiatry. 2004 Dec;75(12):1672-7.

    BACKGROUND: The seed powder of the leguminous plant, Mucuna pruriens has long been used in traditional Ayurvedic Indian medicine for diseases including parkinsonism. We have assessed the clinical effects and levodopa (L-dopa) pharmacokinetics following two different doses of mucuna preparation and compared them with standard L-dopa/carbidopa (LD/CD). METHODS: Eight Parkinson’s disease patients with a short duration L-dopa response and on period dyskinesias completed a randomised, controlled, double blind crossover trial. Patients were challenged with single doses of 200/50 mg LD/CD, and 15 and 30 g of mucuna preparation in randomised order at weekly intervals. L-dopa pharmacokinetics were determined, and Unified Parkinson’s Disease Rating Scale and tapping speed were obtained at baseline and repeatedly during the 4 h following drug ingestion. Dyskinesias were assessed using modified AIMS and Goetz scales. RESULTS: Compared with standard LD/CD, the 30 g mucuna preparation led to a considerably faster onset of effect (34.6 v 68.5 min; p = 0.021), reflected in shorter latencies to peak L-dopa plasma concentrations. Mean on time was 21.9% (37 min) longer with 30 g mucuna than with LD/CD (p = 0.021); peak L-dopa plasma concentrations were 110% higher and the area under the plasma concentration v time curve (area under curve) was 165.3% larger (p = 0.012). No significant differences in dyskinesias or tolerability occurred. CONCLUSIONS: The rapid onset of action and longer on time without concomitant increase in dyskinesias on mucuna seed powder formulation suggest that this natural source of L-dopa might possess advantages over conventional L-dopa preparations in the long term management of PD. Assessment of long term efficacy and tolerability in a randomised, controlled study is warranted.

    Neuroprotective effects of the antiparkinson drug Mucuna pruriens.
    Phytother Res. 2004 Sep;18(9):706-12.

    Mucuna pruriens possesses significantly higher antiparkinson activity compared with levodopa in the 6-hydroxydopamine (6-OHDA) lesioned rat model of Parkinson’s disease. The present study evaluated the neurorestorative effect of Mucuna pruriens cotyledon powder on the nigrostriatal tract of 6-OHDA lesioned rats. Mucuna pruriens cotyledon powder significantly increased the brain mitochondrial complex-I activity but did not affect the total monoamine oxidase activity (in vitro). Unlike synthetic levodopa treatment, Mucuna pruriens cotyledon powder treatment significantly restored the endogenous levodopa, dopamine, norepinephrine and serotonin content in the substantia nigra. Nicotine adenine dinucleotide (NADH) and coenzyme Q-10, that are shown to have a therapeutic benefit in Parkinson’s disease, were present in the Mucuna pruriens cotyledon powder. Earlier studies showed that Mucuna pruriens treatment controls the symptoms of Parkinson’s disease. This additional finding of a neurorestorative benefit by Mucuna pruriens cotyledon powder on the degenerating dopaminergic neurons in the substantia nigra may be due to increased complex-I activity and the presence of NADH and coenzyme Q-10.

    Googla efter loggar på USP´s ”Powerfull” (den nya varianten) Den innehåller l-dopa,det borde finnas lite loggar ute med tränande.

Viewing 5 posts - 1 through 5 (of 5 total)
  • You must be logged in to reply to this topic.